BACKGROUND: Occasional cases of acyclovir resistance have been documented in the treatment of herpes simplex virus (HSV) infection. Thirty-eight subjects with acyclovir-resistant infections were identified in an epidemiological surveillance program involving 1811 HSV-infected subjects in France. METHODS: Twenty-three index cases from whom acyclovir-resistant HSV strains had been isolated were compared with 46 control subjects matched for immunological status. Sociodemographic characteristics, features of the acyclovir-resistant HSV episode, history of HSV infection, treatment, outcome, and immunological history were recorded. RESULTS: Twenty-two index case patients presented with immunodepression. Sixty-five percent reported clinically manifest recurrences, compared with 33% of matched control subjects. Significantly more index case patients had used antiviral drugs, and they had used them more often than had control subjects. However, 26.1% of index case patients reported no antiviral exposure in the previous 2 years. Two-thirds of the strains recovered from the index case patients were isolated because of suspicion of clinical resistance to acyclovir. CONCLUSIONS: Clinical treatment resistance is associated with acyclovir-resistant HSV strains, but acyclovir-resistant strains were also isolated from treatment-naive subjects.
BACKGROUND: Occasional cases of acyclovir resistance have been documented in the treatment of herpes simplex virus (HSV) infection. Thirty-eight subjects with acyclovir-resistant infections were identified in an epidemiological surveillance program involving 1811 HSV-infected subjects in France. METHODS: Twenty-three index cases from whom acyclovir-resistant HSV strains had been isolated were compared with 46 control subjects matched for immunological status. Sociodemographic characteristics, features of the acyclovir-resistant HSV episode, history of HSV infection, treatment, outcome, and immunological history were recorded. RESULTS: Twenty-two index case patients presented with immunodepression. Sixty-five percent reported clinically manifest recurrences, compared with 33% of matched control subjects. Significantly more index case patients had used antiviral drugs, and they had used them more often than had control subjects. However, 26.1% of index case patients reported no antiviral exposure in the previous 2 years. Two-thirds of the strains recovered from the index case patients were isolated because of suspicion of clinical resistance to acyclovir. CONCLUSIONS: Clinical treatment resistance is associated with acyclovir-resistant HSV strains, but acyclovir-resistant strains were also isolated from treatment-naive subjects.
Authors: Leonardo D'Aiuto; Kelly Williamson; Peter Dimitrion; James McNulty; Carla E Brown; Chanti Babu Dokuburra; Alexander J Nielsen; Wen Jing Lin; Paolo Piazza; Mark E Schurdak; Joel Wood; Robert H Yolken; Paul R Kinchington; David C Bloom; Vishwajit L Nimgaonkar Journal: Antiviral Res Date: 2017-03-23 Impact factor: 5.970
Authors: Ella J Ariza-Heredia; Roy F Chemaly; Lokesh R Shahani; Ying Jang; Richard E Champlin; Victor E Mulanovich Journal: Transpl Int Date: 2018-03-13 Impact factor: 3.782
Authors: Lora McClain; Yun Zhi; Hoyee Cheng; Ayantika Ghosh; Paolo Piazza; Michael B Yee; Santosh Kumar; Jadranka Milosevic; David C Bloom; Ravit Arav-Boger; Paul R Kinchington; Robert Yolken; Vishwajit Nimgaonkar; Leonardo D'Aiuto Journal: Antiviral Res Date: 2015-06-12 Impact factor: 5.970
Authors: Elizabeth Cerceo; Ebbing Lautenbach; Darren R Linkin; Warren B Bilker; Ingi Lee Journal: Infect Control Hosp Epidemiol Date: 2009-05 Impact factor: 3.254